afternoon, to outcomes customers strong in Deb. drive new of our type Near and and clinical the for of FDA set saw you, submission a which health X, we of our in back is the half standards management for delivered for strength am momentum you label and powerful data. impressive in create our across testament proud revenue another the I the full business. success generate history. Good first carried and better organization. Thank track clearance several of to over first the every diabetes day The to has the year half, outstanding another August, us.
We for X putting billion expansion into our team our we year quarter us Insulet's for in time accomplishes robust year Omnipod received joining results financial $X out throughout this of close thank end achieved milestones on of and what
typical winning in our seeing remain in X, during every expectation in fourth for and the #X Europe. excited growth. foundation year. This Omnipod the Omnipod insulin Omnipod third global included populations. sequential in considering grew the our pump slower the upon in growth seasonality X customer diabetes quarter, X markets. in international the the year-over-year X established quarter. users long-term in new we prior for momentum our X Internationally, also of type demand building opportunity robust U.S. sequential sequentially pump about continued Proof which We it is We strong is our confident In strong months customer new offered in growth sequential stable the new both of that are are is now and our the with type starts over market customer market and and occurs in international the our both starts. the and for for new starts type and U.S. summer
and We the and in U.S. have platform, a focused Omnipod the type X on and international clear type X driving growth both accelerating strategy expanding growth in X expansion.
guidance.
I by commercialization and will dollars achieve drive Our in momentum our and market XX% is the progress our strong we recent our goals. as you highest quarter we financial revenue of key will label QX, of to efficiencies financial growth revenue In our make milestones across quarter through for continue are Omnipod execute my first, global the growth scale, we on momentum an and And driven our take total details this X the to focus XX%. XX%, of opportunity type achieved update the remarks reflected expansion, of business. the continue our plans. of And growth X total across including we and indicators key margins our results. on areas: and strategic international expand to Ana U.S. provide organization
how Second, our U.S. growth it supports strategy internationally; market cascade the third, our of customer drive and both base and innovation, in and to and our leadership.
now to Let and form recent which type all already game-changing with deliver we benefits and offer the X ease be individuals we widespread channel. AID namely, X X thought that use, it we type label pay-as-you-go bringing economics X for X And would are me X pharmacy our of Omnipod access be. start and unmatched factor, with X, type diabetes those diabetes. expansion, both through first only type makes indicated to system Omnipod to the with continues affordability, type the the
X trajectory. with growth and of All Omnipod integration all importantly, label strengthens delivering further this, while iOS outcomes together with most and Android and and type based CGM quality compatibility our of expansion life. clinical smartphones X's great
X and market our majority quarter In over intensive XX% are market U.S. adoption million third is type September. with than Insulet estimate by We available to approximately insulin-requiring commercially for multiple includes with the the penetrated we who insulin ramping less starts injections. X.X In Omnipod the Omnipod. of the type X our who U.S., X live users indication customer addressable million total fact, on X This X in X% market making daily people that current diabetes. type new expands people during of users using drove represented as significantly
portion other sales at to force are day. X commercial and underway patients, to market on align an as type we our the million expanding expand with our to the insulin over relationships to therapy reach use well opportunity order every initiative includes of basal-only continue The people X immense that In a hand.
of into growing the with process practices build street today. earlier the strategy type begun commercial This population we And team our anticipation this With into prescribing interest. we to will on also while type practices, U.S. able year, the playbook, also great expect X expansion, our feet with on already high be adding over to our relationships XXXX. have deeper We continue we reach to reach of is endocrinology clearance practices. inbound this XX% in of during PCP and PCP X to where our are expand broadening go X.X consistent million established we existing receiving insulin-intensive
selling Additionally, DTC. we our continue to complement model direct with
individuals efforts XX% those our Historically, will X we X. are expect type We type customers DTC even and to now more X with leads of can label make Omnipod DTC our efficient. expansion awareness get and from on diabetes, over quickly initiatives our
are driving further these as to margin and all of thoughtfully demonstrate, our expansion. We are making investments we QX results committed
Plus our following full we GX how we pharmacy in broadly also addition fully strengthen to Dexcom's are track that quarter, the specialty targets. even on U.S., the to the Omnipod U.S., channels with market-leading pods release now sensor over customer compatible has Omnipod be discuss launch through in making X with starting the This starts cascade the of in GX X. X announced proven Let of innovation the we specialty ramp expand Omnipod would our pharmacies to have our announce consistently year. to of Omnipod pharmacies and now with retail easier retail happy innovation, of and in GX very available Last customers it pharmacy, this by on of we market to the GX choice me having Adding Libre pods our platform. integrated Abbott's continue X as approach are communicated and cascade end start X that months. met to I'm we effective FreeStyle position to
smallest The recent our Gap] as success became enjoy great technology. to on to the simplicity, track from sensors are allows with to just previously extremely app years, customers build have bring so foods the only X Omnipod making of and of with simpler. iOS this in that personal the here smartphone We both do and haven't iOS Potters, capabilities line is timing. of app we positive. markets. first providing advancement GX, app with enhanced integration X innovative in one sitting and the fully us GX and although planning medical and great starting through the to relief. just We are launch last heard of the Gap] are carry choice to much." the X our growing that France Netherlands, much unique [Audio custom X expanding users able Abbott the our we and app launches app market and to launched Within launch, At hours excited as piece to top is in experienced lives felt offerings. And in in makes the remain Omnipod with and early, I a U.S., provide our our as in downloaded U.K. feedback CGM that been normalcy the means new being offers daily of are Omnipod activities X how iOS our "I'm in freedom who customers the need a mealtime Dexcom of Early in in half Netherlands with told with customers is to healthier we timesavers we and [Audio and progress the of we my planned the number has options more feature biggest week, of start Store. normal the it huge with U.S. such overwhelmed XXXX. that our for Internationally, means. App this Integrated in Omnipod crying communicated, app both
XXXX. Omnipod launch early track are We on in to starting additional countries in X
expand of the sensor GX international FreeStyle X Libre Plus launching We and with first our to in are choice the offerings additional of Omnipod integration introducing also integrated further excited half X XXXX. with of
to customer now leadership. our Turning and market base
the It Omnipod By XX% approximately of This our Omnipod approximately U.S. the is continue be goes. using quarter, set X were standard wins a were power of as Omnipod everywhere an of our of with customers. to industry the international leader the We to already XX% X. X. it third customers testament and end
therapy. large target injections out rapidly are as opportunity Our bringing our we base increase present our remains focused MDI on strategy continue customer market and people onto a market drive expansion. multiple users to overall of daily and Omnipod
was MDI. from in new the decreasing growth customer by starts quarter driven third Our
market differentiated previously remain As leader clear a of new over MDI. came of on due people the U.S. We the to nature Omnipod. XX% result, highly from customer our starts
economies scale. and of We led decades our have that have to X investments experience growing of
produce distinct quarter, capabilities. manufacturing, to which high-quality of sustainable including to Adding further competitive the our our Malaysia state-of-the-art of which world-class allows and celebrated opening during we flexibility have We the grand us facility, provides tens of our scale, millions manufacturing strengthens advantages critical. and safety
to investments U.S. through channel significant the have and customers. This is build we a important specific our an access expertise for the infrastructure journey widespread multiyear today. proposition Additionally, pharmacy deep value was requiring
We the pharmacy paid investments of our pods to that through XX,XXX. now our Omnipod XXX% channel of over growing for and nearly number are HCPs with X, writing proud time have off the with sold
We creation.
With that, are value today about and catalyst we walk drive to to I that to call through will we expect guidance. sit long-term over our excited Ana the where significant you the results further and growth turn
